124 related articles for article (PubMed ID: 15199413)
1. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
[TBL] [Abstract][Full Text] [Related]
2. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
3. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
4. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Dong S; Kang S; Lonial S; Khoury HJ; Viallet J; Chen J
Leukemia; 2008 Mar; 22(3):572-7. PubMed ID: 18079735
[TBL] [Abstract][Full Text] [Related]
5. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
6. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.
Tomasson MH; Sternberg DW; Williams IR; Carroll M; Cain D; Aster JC; Ilaria RL; Van Etten RA; Gilliland DG
J Clin Invest; 2000 Feb; 105(4):423-32. PubMed ID: 10683371
[TBL] [Abstract][Full Text] [Related]
7. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Tam WF; Gu TL; Chen J; Lee BH; Bullinger L; Fröhling S; Wang A; Monti S; Golub TR; Gilliland DG
Blood; 2008 Sep; 112(5):1981-92. PubMed ID: 18559972
[TBL] [Abstract][Full Text] [Related]
8. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M
Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760
[TBL] [Abstract][Full Text] [Related]
9. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
Unwin RD; Sternberg DW; Lu Y; Pierce A; Gilliland DG; Whetton AD
J Biol Chem; 2005 Feb; 280(8):6316-26. PubMed ID: 15569670
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
[TBL] [Abstract][Full Text] [Related]
11. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
Sternberg DW; Tomasson MH; Carroll M; Curley DP; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland DG
Blood; 2001 Dec; 98(12):3390-7. PubMed ID: 11719379
[TBL] [Abstract][Full Text] [Related]
12. The coupling of TEL/PDGFbetaR to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases.
Wheadon H; Welham MJ
Blood; 2003 Aug; 102(4):1480-9. PubMed ID: 12714513
[TBL] [Abstract][Full Text] [Related]
13. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
14. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
Pecquet C; Nyga R; Penard-Lacronique V; Smithgall TE; Murakami H; Régnier A; Lassoued K; Gouilleux F
Oncogene; 2007 Mar; 26(11):1577-85. PubMed ID: 16953222
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V
Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338
[TBL] [Abstract][Full Text] [Related]
16. Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation.
Chen J; Williams IR; Kutok JL; Duclos N; Anastasiadou E; Masters SC; Fu H; Gilliland DG
Blood; 2004 Jul; 104(2):535-42. PubMed ID: 15054045
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.
Kim H; Gillis LC; Jarvis JD; Yang S; Huang K; Der S; Barber DL
BMC Cancer; 2011 Dec; 11():528. PubMed ID: 22204395
[TBL] [Abstract][Full Text] [Related]
18. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
19. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Chiang NJ; Yen CC; Li CF; Chen LT
Oncotarget; 2014 Nov; 5(22):11723-36. PubMed ID: 25375091
[TBL] [Abstract][Full Text] [Related]
20. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
